SCHEMBL4905928

SCHEMBL4905928

Oc1cccc(Nc2nccc(-c3cccc(Cl)c3)n2)c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 5/20 0.72
CAMK2D Q13557 6/20 0.70
ABL1 P00519 1/20 0.67
BCR P11274 1/20 0.67
PRKCA P17252 1/20 0.67
PRKCD Q05655 1/20 0.67
SYK P43405 2/20 0.59
CDK2 P24941 4/20 0.58
CDK4 P11802 3/20 0.58
CDK1 P06493 2/20 0.58
SMG1 Q96Q15 2/20 0.58
MAPT P10636 2/20 0.58
NPC1 O15118 1/20 0.58
CCNT1 O60563 1/20 0.58
CCNB1 P14635 1/20 0.58
XBP1 P17861 1/20 0.58
CCNA2 P20248 1/20 0.58
CCND1 P24385 1/20 0.58
CCNE1 P24864 1/20 0.58
MAPK1 P28482 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4737537 0.91 SYK (0.67) PLK1CAMK2DABL1BCRPRKCA
SCHEMBL4735460 0.88 PLK1 (0.82) PLK1CAMK2DABL1BCRPRKCA
SCHEMBL14651462 0.87 PLK1 (0.84) PLK1CAMK2DABL1BCRPRKCA
SCHEMBL4734608 0.86 PIK3CG (0.69) PLK1CAMK2DABL1BCRPRKCA
SCHEMBL5733933 0.86 CAMK2D (0.71) PLK1CAMK2DABL1BCRPRKCA
SCHEMBL2945644 0.85 PLK1 (0.79) PLK1CAMK2DABL1BCRSYK
SCHEMBL27116530 0.84 PLK1 (0.68) PLK1CAMK2DABL1BCRPRKCA
SCHEMBL4732841 0.84 PLK1 (1.00) PLK1CAMK2DABL1BCRPRKCA
SCHEMBL14254277 0.83 CAMK2D (0.71) PLK1CAMK2DABL1BCRPRKCA
SCHEMBL27612399 0.82 PIK3CA (0.74) PLK1CAMK2DABL1BCRPRKCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080153822-A1 Methods of treating pain INGENIUM PHARMACEUTICALS GMBH (DE) 2008-06-26 US claimed
US-20070021419-A1 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors CYCLACEL LIMITED (GB) 2007-01-25 US disclosed
US-20070021419-A1 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors CYCLACEL LIMITED (GB) 2007-01-25 US disclosed
US-20070021419-A1 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors CYCLACEL LIMITED (GB) 2007-01-25 US disclosed
CN-1860104-A 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors CYCLACEL LTD (GB) 2006-11-08 CN disclosed
EP-1648875-A1 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS Cyclacel Limited (GB) 2006-04-26 EP disclosed
WO-2005012262-A1 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS CYCLACEL LIMITED (GB) 2005-02-10 WO disclosed
WO-2005012262-A1 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS CYCLACEL LIMITED (GB) 2005-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021419-A1 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors GRK3, NCOR1, GRM3 PLK1 1603/4885CAMK2D 1264/4885ABL1 684/4885
US-20080153822-A1 Methods of treating pain OPRL1, ACHE, OPRK1 PLK1 3544/4885CAMK2D 1498/4885ABL1 1154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.